OSCR

Oscar Health, Inc. (OSCR) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Oscar Health, Inc. is a healthcare technology company operating primarily in the individual and small group markets via federal and state exchanges. As of September 30, 2024, the company reported approximately 1.65 million members. The company exited the Medicare Advantage market for the 2024 plan year and announced it will not renew its Cigna+Oscar Small Group partnership after December 31, 2024, effectively exiting the small group market.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 68% year-over-year (YoY) for Q3 and 53% YoY for the nine-month period, driven primarily by a 68% increase in membership and rate increases.
• Profitability: The company returned to profitability on a trailing twelve-month basis, reporting net income of $179.4 million for the nine months ended September 30, 2024, compared to a net loss of $120.8 million in the same period in 2023.
• Medical Costs: Medical expenses increased 72% YoY in Q3, consistent with membership growth. The MLR increased slightly to 84.6% in Q3 due to higher costs from Special Enrollment Period (SEP) members and COVID-related costs, though it improved to 79.5% for the nine-month period due to favorable prior period development.
• Operating Efficiency: The SG&A expense ratio improved significantly to 19.0% in Q3 (down from 22.6% in Q3 2023), reflecting fixed cost leverage and variable cost efficiencies.
• Investment Portfolio: Investment income increased 19% YoY in Q3 due to a larger asset base and higher interest rates. Total investments grew significantly, with long-term investments rising from $365.3 million at year-end 2023 to $1.93 billion at September 30, 2024.

Guidance, Outlook, and Risks

• Strategic Shifts: Oscar will cease offering small group products effective December 15, 2024, following the non-renewal of the Cigna+Oscar partnership. The company will provide run-off services through 2026.
• Debt Conversion: The conditional conversion feature for the $305 million Convertible Senior Notes due 2031 was satisfied in Q3 2024. Holders may convert the notes during Q4 2024. The notes have not yet been converted.
• Liquidity: The company maintains strong liquidity with $1.2 billion in cash and cash equivalents. Statutory capital and surplus for health insurance subsidiaries were $1.07 billion, exceeding minimum requirements. Subsidiaries paid $133 million in dividends/loan repayments to the parent company in the first nine months of 2024.
• Risks: Key risks include regulatory changes (Medicaid unwinding, ACA broker rules), the uncertainty of risk adjustment transfer estimates, and the potential impact of the Change Healthcare cybersecurity incident (though no member data breach was reported). Legal proceedings, including a securities class action regarding the IPO, remain ongoing with indeterminate outcomes.

Investor Verification Checklist

• Debt Conversion Impact: Verify if the $305 million convertible notes are converted in Q4 2024 and the resulting dilution or cash settlement impact.
• Small Group Run-off: Monitor the financial impact of exiting the small group market and the execution of the Cigna+Oscar run-off period.
• MLR Sustainability: Assess whether the Q3 MLR increase (84.6%) is a seasonal anomaly or a trend driven by SEP member risk profiles.
• Regulatory Capital: Confirm continued compliance with state statutory capital requirements as membership grows and medical costs fluctuate.
• Legal Contingencies: Track developments in the Carpenter v. Oscar Health, Inc. securities class action and other regulatory investigations.